Loading…

The syndecan family of proteoglycans. Novel receptors mediating internalization of atherogenic lipoproteins in vitro

Cell-surface heparan sulfate proteoglycans have been shown to participate in lipoprotein catabolism, but the roles of specific proteoglycan classes have not been examined previously. Here, we studied the involvement of the syndecan proteoglycan family. First, transfection of CHO cells with expressio...

Full description

Saved in:
Bibliographic Details
Published in:The Journal of clinical investigation 1997-09, Vol.100 (6), p.1611-1622
Main Authors: Fuki, I V, Kuhn, K M, Lomazov, I R, Rothman, V L, Tuszynski, G P, Iozzo, R V, Swenson, T L, Fisher, E A, Williams, K J
Format: Article
Language:English
Subjects:
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c435t-da9027e5b8bda7b6ac1dfa847da8d9042f5976a0f12086cb0e6850b3b438d5373
cites
container_end_page 1622
container_issue 6
container_start_page 1611
container_title The Journal of clinical investigation
container_volume 100
creator Fuki, I V
Kuhn, K M
Lomazov, I R
Rothman, V L
Tuszynski, G P
Iozzo, R V
Swenson, T L
Fisher, E A
Williams, K J
description Cell-surface heparan sulfate proteoglycans have been shown to participate in lipoprotein catabolism, but the roles of specific proteoglycan classes have not been examined previously. Here, we studied the involvement of the syndecan proteoglycan family. First, transfection of CHO cells with expression vectors for several syndecan core proteins produced parallel increases in the cell association and degradation of lipoproteins enriched in lipoprotein lipase, a heparan-binding protein. Second, a chimeric construct, FcR-Synd1, that consists of the ectodomain of the IgG Fc receptor Ia linked to the highly conserved transmembrane and cytoplasmic domains of syndecan-1 directly mediated efficient internalization, in a process triggered by ligand clustering. Third, internalization of lipase-enriched lipoproteins via syndecan-1 and of clustered IgGs via the chimera showed identical kinetics (t1/2 = 1 h) and identical dose-response sensitivities to cytochalasin B, which disrupts microfilaments, and to genistein, which inhibits tyrosine kinases. In contrast, internalization of the receptor-associated protein, which proceeds via coated pits, showed a t1/2 < 15 min, limited sensitivity to cytochalasin B, and complete insensitivity to genistein. Thus, syndecan proteoglycans can directly mediate ligand catabolism through a pathway with characteristics distinct from coated pits, and might act as receptors for atherogenic lipoproteins and other ligands in vivo.
doi_str_mv 10.1172/jci119685
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_508343</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>79279239</sourcerecordid><originalsourceid>FETCH-LOGICAL-c435t-da9027e5b8bda7b6ac1dfa847da8d9042f5976a0f12086cb0e6850b3b438d5373</originalsourceid><addsrcrecordid>eNpVkU9PAyEQxTlotFYPfgATTiYeqrCw3eXgwTT-qWn0omfCsrMtDYUVaJP66UXbGE0mIQO_92bIQ-ickmtKq-JmqQ2lYlyXB2hASEFHomL1MTqJcUkI5bzkR-hIFIJTRgYovS0Ax61rQSuHO7Uydot9h_vgE_i53ebreI1f_AYsDqChTz5EvILWqGTcHBuXIDhlzWfuvfvWqrSA4OfgjMbW9P7Hy7iYWbwxKfhTdNgpG-Fsfw7R-8P92-RpNHt9nE7uZiPNWZlGrRKkqKBs6qZVVTNWmradqnnVqroVhBddKaqxIh0tSD3WDYH8a9KwhrO6LVnFhuh259uvm7yxBpeCsrIPZqXCVnpl5P8XZxZy7jeyJDXjLOsv9_rgP9YQk1yZqMFa5cCvo6xEkYuJDF7tQB18jAG63xmUyO9U5PNkukslsxd_l_ol95GwLwBYjlc</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>79279239</pqid></control><display><type>article</type><title>The syndecan family of proteoglycans. Novel receptors mediating internalization of atherogenic lipoproteins in vitro</title><source>Open Access: PubMed Central</source><source>EZB Electronic Journals Library</source><creator>Fuki, I V ; Kuhn, K M ; Lomazov, I R ; Rothman, V L ; Tuszynski, G P ; Iozzo, R V ; Swenson, T L ; Fisher, E A ; Williams, K J</creator><creatorcontrib>Fuki, I V ; Kuhn, K M ; Lomazov, I R ; Rothman, V L ; Tuszynski, G P ; Iozzo, R V ; Swenson, T L ; Fisher, E A ; Williams, K J</creatorcontrib><description>Cell-surface heparan sulfate proteoglycans have been shown to participate in lipoprotein catabolism, but the roles of specific proteoglycan classes have not been examined previously. Here, we studied the involvement of the syndecan proteoglycan family. First, transfection of CHO cells with expression vectors for several syndecan core proteins produced parallel increases in the cell association and degradation of lipoproteins enriched in lipoprotein lipase, a heparan-binding protein. Second, a chimeric construct, FcR-Synd1, that consists of the ectodomain of the IgG Fc receptor Ia linked to the highly conserved transmembrane and cytoplasmic domains of syndecan-1 directly mediated efficient internalization, in a process triggered by ligand clustering. Third, internalization of lipase-enriched lipoproteins via syndecan-1 and of clustered IgGs via the chimera showed identical kinetics (t1/2 = 1 h) and identical dose-response sensitivities to cytochalasin B, which disrupts microfilaments, and to genistein, which inhibits tyrosine kinases. In contrast, internalization of the receptor-associated protein, which proceeds via coated pits, showed a t1/2 &lt; 15 min, limited sensitivity to cytochalasin B, and complete insensitivity to genistein. Thus, syndecan proteoglycans can directly mediate ligand catabolism through a pathway with characteristics distinct from coated pits, and might act as receptors for atherogenic lipoproteins and other ligands in vivo.</description><identifier>ISSN: 0021-9738</identifier><identifier>DOI: 10.1172/jci119685</identifier><identifier>PMID: 9294130</identifier><language>eng</language><publisher>United States</publisher><subject>Animals ; Chloroquine - pharmacology ; CHO Cells ; Cricetinae ; Cytochalasin B - pharmacology ; Dose-Response Relationship, Drug ; Genistein - pharmacology ; Heparin - pharmacology ; Humans ; Lipoprotein Lipase - metabolism ; Lipoproteins, LDL - metabolism ; Lipoproteins, LDL - pharmacokinetics ; Low Density Lipoprotein Receptor-Related Protein-1 ; Membrane Glycoproteins - genetics ; Membrane Glycoproteins - metabolism ; Proteoglycans - genetics ; Proteoglycans - metabolism ; Rats ; Receptors, IgG - genetics ; Receptors, IgG - metabolism ; Receptors, Immunologic - physiology ; Receptors, LDL - physiology ; Recombinant Fusion Proteins - pharmacology ; Syndecan-1 ; Syndecans ; Thrombospondins - pharmacology ; Transfection</subject><ispartof>The Journal of clinical investigation, 1997-09, Vol.100 (6), p.1611-1622</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c435t-da9027e5b8bda7b6ac1dfa847da8d9042f5976a0f12086cb0e6850b3b438d5373</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC508343/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC508343/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9294130$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Fuki, I V</creatorcontrib><creatorcontrib>Kuhn, K M</creatorcontrib><creatorcontrib>Lomazov, I R</creatorcontrib><creatorcontrib>Rothman, V L</creatorcontrib><creatorcontrib>Tuszynski, G P</creatorcontrib><creatorcontrib>Iozzo, R V</creatorcontrib><creatorcontrib>Swenson, T L</creatorcontrib><creatorcontrib>Fisher, E A</creatorcontrib><creatorcontrib>Williams, K J</creatorcontrib><title>The syndecan family of proteoglycans. Novel receptors mediating internalization of atherogenic lipoproteins in vitro</title><title>The Journal of clinical investigation</title><addtitle>J Clin Invest</addtitle><description>Cell-surface heparan sulfate proteoglycans have been shown to participate in lipoprotein catabolism, but the roles of specific proteoglycan classes have not been examined previously. Here, we studied the involvement of the syndecan proteoglycan family. First, transfection of CHO cells with expression vectors for several syndecan core proteins produced parallel increases in the cell association and degradation of lipoproteins enriched in lipoprotein lipase, a heparan-binding protein. Second, a chimeric construct, FcR-Synd1, that consists of the ectodomain of the IgG Fc receptor Ia linked to the highly conserved transmembrane and cytoplasmic domains of syndecan-1 directly mediated efficient internalization, in a process triggered by ligand clustering. Third, internalization of lipase-enriched lipoproteins via syndecan-1 and of clustered IgGs via the chimera showed identical kinetics (t1/2 = 1 h) and identical dose-response sensitivities to cytochalasin B, which disrupts microfilaments, and to genistein, which inhibits tyrosine kinases. In contrast, internalization of the receptor-associated protein, which proceeds via coated pits, showed a t1/2 &lt; 15 min, limited sensitivity to cytochalasin B, and complete insensitivity to genistein. Thus, syndecan proteoglycans can directly mediate ligand catabolism through a pathway with characteristics distinct from coated pits, and might act as receptors for atherogenic lipoproteins and other ligands in vivo.</description><subject>Animals</subject><subject>Chloroquine - pharmacology</subject><subject>CHO Cells</subject><subject>Cricetinae</subject><subject>Cytochalasin B - pharmacology</subject><subject>Dose-Response Relationship, Drug</subject><subject>Genistein - pharmacology</subject><subject>Heparin - pharmacology</subject><subject>Humans</subject><subject>Lipoprotein Lipase - metabolism</subject><subject>Lipoproteins, LDL - metabolism</subject><subject>Lipoproteins, LDL - pharmacokinetics</subject><subject>Low Density Lipoprotein Receptor-Related Protein-1</subject><subject>Membrane Glycoproteins - genetics</subject><subject>Membrane Glycoproteins - metabolism</subject><subject>Proteoglycans - genetics</subject><subject>Proteoglycans - metabolism</subject><subject>Rats</subject><subject>Receptors, IgG - genetics</subject><subject>Receptors, IgG - metabolism</subject><subject>Receptors, Immunologic - physiology</subject><subject>Receptors, LDL - physiology</subject><subject>Recombinant Fusion Proteins - pharmacology</subject><subject>Syndecan-1</subject><subject>Syndecans</subject><subject>Thrombospondins - pharmacology</subject><subject>Transfection</subject><issn>0021-9738</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1997</creationdate><recordtype>article</recordtype><recordid>eNpVkU9PAyEQxTlotFYPfgATTiYeqrCw3eXgwTT-qWn0omfCsrMtDYUVaJP66UXbGE0mIQO_92bIQ-ickmtKq-JmqQ2lYlyXB2hASEFHomL1MTqJcUkI5bzkR-hIFIJTRgYovS0Ax61rQSuHO7Uydot9h_vgE_i53ebreI1f_AYsDqChTz5EvILWqGTcHBuXIDhlzWfuvfvWqrSA4OfgjMbW9P7Hy7iYWbwxKfhTdNgpG-Fsfw7R-8P92-RpNHt9nE7uZiPNWZlGrRKkqKBs6qZVVTNWmradqnnVqroVhBddKaqxIh0tSD3WDYH8a9KwhrO6LVnFhuh259uvm7yxBpeCsrIPZqXCVnpl5P8XZxZy7jeyJDXjLOsv9_rgP9YQk1yZqMFa5cCvo6xEkYuJDF7tQB18jAG63xmUyO9U5PNkukslsxd_l_ol95GwLwBYjlc</recordid><startdate>19970915</startdate><enddate>19970915</enddate><creator>Fuki, I V</creator><creator>Kuhn, K M</creator><creator>Lomazov, I R</creator><creator>Rothman, V L</creator><creator>Tuszynski, G P</creator><creator>Iozzo, R V</creator><creator>Swenson, T L</creator><creator>Fisher, E A</creator><creator>Williams, K J</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>19970915</creationdate><title>The syndecan family of proteoglycans. Novel receptors mediating internalization of atherogenic lipoproteins in vitro</title><author>Fuki, I V ; Kuhn, K M ; Lomazov, I R ; Rothman, V L ; Tuszynski, G P ; Iozzo, R V ; Swenson, T L ; Fisher, E A ; Williams, K J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c435t-da9027e5b8bda7b6ac1dfa847da8d9042f5976a0f12086cb0e6850b3b438d5373</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1997</creationdate><topic>Animals</topic><topic>Chloroquine - pharmacology</topic><topic>CHO Cells</topic><topic>Cricetinae</topic><topic>Cytochalasin B - pharmacology</topic><topic>Dose-Response Relationship, Drug</topic><topic>Genistein - pharmacology</topic><topic>Heparin - pharmacology</topic><topic>Humans</topic><topic>Lipoprotein Lipase - metabolism</topic><topic>Lipoproteins, LDL - metabolism</topic><topic>Lipoproteins, LDL - pharmacokinetics</topic><topic>Low Density Lipoprotein Receptor-Related Protein-1</topic><topic>Membrane Glycoproteins - genetics</topic><topic>Membrane Glycoproteins - metabolism</topic><topic>Proteoglycans - genetics</topic><topic>Proteoglycans - metabolism</topic><topic>Rats</topic><topic>Receptors, IgG - genetics</topic><topic>Receptors, IgG - metabolism</topic><topic>Receptors, Immunologic - physiology</topic><topic>Receptors, LDL - physiology</topic><topic>Recombinant Fusion Proteins - pharmacology</topic><topic>Syndecan-1</topic><topic>Syndecans</topic><topic>Thrombospondins - pharmacology</topic><topic>Transfection</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Fuki, I V</creatorcontrib><creatorcontrib>Kuhn, K M</creatorcontrib><creatorcontrib>Lomazov, I R</creatorcontrib><creatorcontrib>Rothman, V L</creatorcontrib><creatorcontrib>Tuszynski, G P</creatorcontrib><creatorcontrib>Iozzo, R V</creatorcontrib><creatorcontrib>Swenson, T L</creatorcontrib><creatorcontrib>Fisher, E A</creatorcontrib><creatorcontrib>Williams, K J</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>The Journal of clinical investigation</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Fuki, I V</au><au>Kuhn, K M</au><au>Lomazov, I R</au><au>Rothman, V L</au><au>Tuszynski, G P</au><au>Iozzo, R V</au><au>Swenson, T L</au><au>Fisher, E A</au><au>Williams, K J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The syndecan family of proteoglycans. Novel receptors mediating internalization of atherogenic lipoproteins in vitro</atitle><jtitle>The Journal of clinical investigation</jtitle><addtitle>J Clin Invest</addtitle><date>1997-09-15</date><risdate>1997</risdate><volume>100</volume><issue>6</issue><spage>1611</spage><epage>1622</epage><pages>1611-1622</pages><issn>0021-9738</issn><abstract>Cell-surface heparan sulfate proteoglycans have been shown to participate in lipoprotein catabolism, but the roles of specific proteoglycan classes have not been examined previously. Here, we studied the involvement of the syndecan proteoglycan family. First, transfection of CHO cells with expression vectors for several syndecan core proteins produced parallel increases in the cell association and degradation of lipoproteins enriched in lipoprotein lipase, a heparan-binding protein. Second, a chimeric construct, FcR-Synd1, that consists of the ectodomain of the IgG Fc receptor Ia linked to the highly conserved transmembrane and cytoplasmic domains of syndecan-1 directly mediated efficient internalization, in a process triggered by ligand clustering. Third, internalization of lipase-enriched lipoproteins via syndecan-1 and of clustered IgGs via the chimera showed identical kinetics (t1/2 = 1 h) and identical dose-response sensitivities to cytochalasin B, which disrupts microfilaments, and to genistein, which inhibits tyrosine kinases. In contrast, internalization of the receptor-associated protein, which proceeds via coated pits, showed a t1/2 &lt; 15 min, limited sensitivity to cytochalasin B, and complete insensitivity to genistein. Thus, syndecan proteoglycans can directly mediate ligand catabolism through a pathway with characteristics distinct from coated pits, and might act as receptors for atherogenic lipoproteins and other ligands in vivo.</abstract><cop>United States</cop><pmid>9294130</pmid><doi>10.1172/jci119685</doi><tpages>12</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0021-9738
ispartof The Journal of clinical investigation, 1997-09, Vol.100 (6), p.1611-1622
issn 0021-9738
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_508343
source Open Access: PubMed Central; EZB Electronic Journals Library
subjects Animals
Chloroquine - pharmacology
CHO Cells
Cricetinae
Cytochalasin B - pharmacology
Dose-Response Relationship, Drug
Genistein - pharmacology
Heparin - pharmacology
Humans
Lipoprotein Lipase - metabolism
Lipoproteins, LDL - metabolism
Lipoproteins, LDL - pharmacokinetics
Low Density Lipoprotein Receptor-Related Protein-1
Membrane Glycoproteins - genetics
Membrane Glycoproteins - metabolism
Proteoglycans - genetics
Proteoglycans - metabolism
Rats
Receptors, IgG - genetics
Receptors, IgG - metabolism
Receptors, Immunologic - physiology
Receptors, LDL - physiology
Recombinant Fusion Proteins - pharmacology
Syndecan-1
Syndecans
Thrombospondins - pharmacology
Transfection
title The syndecan family of proteoglycans. Novel receptors mediating internalization of atherogenic lipoproteins in vitro
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T09%3A12%3A04IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20syndecan%20family%20of%20proteoglycans.%20Novel%20receptors%20mediating%20internalization%20of%20atherogenic%20lipoproteins%20in%20vitro&rft.jtitle=The%20Journal%20of%20clinical%20investigation&rft.au=Fuki,%20I%20V&rft.date=1997-09-15&rft.volume=100&rft.issue=6&rft.spage=1611&rft.epage=1622&rft.pages=1611-1622&rft.issn=0021-9738&rft_id=info:doi/10.1172/jci119685&rft_dat=%3Cproquest_pubme%3E79279239%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c435t-da9027e5b8bda7b6ac1dfa847da8d9042f5976a0f12086cb0e6850b3b438d5373%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=79279239&rft_id=info:pmid/9294130&rfr_iscdi=true